FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2646-2648 June 21, 2007 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bruno, B. PubMed Citation

To the Editor: We are concerned about the effect on clinical practice of the report by Bruno and colleagues comparing a hematopoietic stem-cell autograft followed by an allograft with tandem autografts for newly diagnosed multiple myeloma (March 15 issue),¹ since the conclusions are based on a small sample and cytogenetic data were not available for 64% of the patients. We conducted a study² in which the 5-year survival rate was 68% among 532 patients under 65 years of age who were receiving our Total Therapy 2 (two cycles of melphalan-based chemotherapy, each supported by autologous hematopoietic stem-cell transplantation). These results . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.